Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1998 1
2001 1
2003 1
2005 1
2006 1
2007 4
2008 6
2009 5
2010 7
2011 8
2012 6
2013 4
2014 6
2015 5
2016 12
2017 8
2018 6
2019 6
2020 15
2021 18
2022 20
2023 28
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.
Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, Damasceno A, Avezum A, Dans AML, Gitura B, Hu D, Kamanzi ER, Maklady F, Fana G, Gonzalez-Hermosillo JA, Musuku J, Kazmi K, Zühlke L, Gondwe L, Ma C, Paniagua M, Ogah OS, Molefe-Baikai OJ, Lwabi P, Chillo P, Sharma SK, Cabral TTJ, Tarhuni WM, Benz A, van Eikels M, Krol A, Pattath D, Balasubramanian K, Rangarajan S, Ramasundarahettige C, Mayosi B, Yusuf S; INVICTUS Investigators. Connolly SJ, et al. N Engl J Med. 2022 Sep 15;387(11):978-988. doi: 10.1056/NEJMoa2209051. Epub 2022 Aug 28. N Engl J Med. 2022. PMID: 36036525 Clinical Trial.
BACKGROUND: Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation has been limited. ...
BACKGROUND: Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease-asso …
The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019.
GBD 2019 Cancer Risk Factors Collaborators. GBD 2019 Cancer Risk Factors Collaborators. Lancet. 2022 Aug 20;400(10352):563-591. doi: 10.1016/S0140-6736(22)01438-6. Lancet. 2022. PMID: 35988567 Free PMC article.
BACKGROUND: Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Stu …
BACKGROUND: Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of e …
Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.
Wang TY, Wahed AS, Morris A, Kreuziger LB, Quigley JG, Lamas GA, Weissman AJ, Lopez-Sendon J, Knudson MM, Siegal DM, Kasthuri RS, Alexander AJ, Wahid L, Atassi B, Miller PJ, Lawson JW, Patel B, Krishnan JA, Shapiro NL, Martin DE, Kindzelski AL, Leifer ES, Joo J, Lyu L, Pennella A, Everett BM, Geraci MW, Anstrom KJ, Ortel TL; ACTIV-4C Study Group. Wang TY, et al. Ann Intern Med. 2023 Apr;176(4):515-523. doi: 10.7326/M22-3350. Epub 2023 Mar 21. Ann Intern Med. 2023. PMID: 36940444 Free PMC article. Clinical Trial.
Median age was 54 years, 50.4% were women, 26.5% were Black, and 16.7% were Hispanic; 30.7% had a World Health Organization severity score of 5 or greater, and 11.0% had an International Medical Prevention Registry on Venous Thromboembolism risk prediction score of greater …
Median age was 54 years, 50.4% were women, 26.5% were Black, and 16.7% were Hispanic; 30.7% had a World Health Organization severity score o …
Non-antibiotic interventions for prevention of urinary tract infections in children: a systematic review and meta-analysis of randomized controlled trials.
Meena J, Thomas CC, Kumar J, Raut S, Hari P. Meena J, et al. Eur J Pediatr. 2021 Dec;180(12):3535-3545. doi: 10.1007/s00431-021-04091-2. Epub 2021 Jun 22. Eur J Pediatr. 2021. PMID: 34156540
While low-dose antibiotic prophylaxis has been the mainstay for the prevention of UTI, recent evidence raised concerns over their efficacy and safety. ...RCTs comparing any non-antibiotic interventions with placebo/antibiotics for prevention of UTIs in children were …
While low-dose antibiotic prophylaxis has been the mainstay for the prevention of UTI, recent evidence raised concerns over their eff …
Cervical Cancer Prevention Efforts in India.
Bhatla N, Meena J, Kumari S, Banerjee D, Singh P, Natarajan J. Bhatla N, et al. Indian J Gynecol Oncol. 2021;19(3):41. doi: 10.1007/s40944-021-00526-8. Epub 2021 Jun 2. Indian J Gynecol Oncol. 2021. PMID: 34095455 Free PMC article. Review.
PURPOSE: Cervical cancer is one of the leading cancers among women in India. Its prevention and control require a concerted effort to improve awareness among women regarding primary and secondary prevention strategies as well as access to care for trea …
PURPOSE: Cervical cancer is one of the leading cancers among women in India. Its prevention and control require a conce …
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.
Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, Datir R, Collier DA, Albecka A, Singh S, Pandey R, Brown J, Zhou J, Goonawardane N, Mishra S, Whittaker C, Mellan T, Marwal R, Datta M, Sengupta S, Ponnusamy K, Radhakrishnan VS, Abdullahi A, Charles O, Chattopadhyay P, Devi P, Caputo D, Peacock T, Wattal C, Goel N, Satwik A, Vaishya R, Agarwal M; Indian SARS-CoV-2 Genomics Consortium (INSACOG); Genotype to Phenotype Japan (G2P-Japan) Consortium; CITIID-NIHR BioResource COVID-19 Collaboration; Mavousian A, Lee JH, Bassi J, Silacci-Fegni C, Saliba C, Pinto D, Irie T, Yoshida I, Hamilton WL, Sato K, Bhatt S, Flaxman S, James LC, Corti D, Piccoli L, Barclay WS, Rakshit P, Agrawal A, Gupta RK. Mlcochova P, et al. Nature. 2021 Nov;599(7883):114-119. doi: 10.1038/s41586-021-03944-y. Epub 2021 Sep 6. Nature. 2021. PMID: 34488225 Free PMC article.
Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era....
Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control m …
Risk factors for Coronavirus disease-associated mucormycosis.
Arora U, Priyadarshi M, Katiyar V, Soneja M, Garg P, Gupta I, Bharadiya V, Berry P, Ghosh T, Patel L, Sarda R, Garg S, Agarwal S, Arora V, Ramprasad A, Kumar A, Garg RK, Kodan P, Nischal N, Singh G, Jorwal P, Kumar A, Baitha U, Meena VP, Ray A, Sethi P, Xess I, Vikram N, Sinha S, Biswas A, Thakar A, Bhatnagar S, Trikha A, Wig N. Arora U, et al. J Infect. 2022 Mar;84(3):383-390. doi: 10.1016/j.jinf.2021.12.039. Epub 2021 Dec 30. J Infect. 2022. PMID: 34974056 Free PMC article.
We aimed to identify risk factors that may explain the burden of cases and help develop preventive strategies. METHODS: We performed a case-control study comparing cases diagnosed with CAM and taking controls as recovered COVID 19 patients who did not develop mucormycosis. …
We aimed to identify risk factors that may explain the burden of cases and help develop preventive strategies. METHODS: We performed a case- …
Demystifying BCG Vaccine and COVID-19 Relationship.
Kumar J, Meena J. Kumar J, et al. Indian Pediatr. 2020 Jun 15;57(6):588-589. doi: 10.1007/s13312-020-1872-0. Epub 2020 Apr 30. Indian Pediatr. 2020. PMID: 32358227 Free PMC article. No abstract available.
148 results